Quantcast

Latest acute coronary syndromes Stories

2014-03-27 08:34:15

Sub-analyses Investigate the Effects of alogliptin on Cardiovascular Mortality Rates and Hospitalization for Heart Failure in Type 2 Diabetes Patients with Recent Acute Coronary Syndrome WASHINGTON and OSAKA, Japan, March 27, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) will present sub-analyses from the global EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome)...

2014-01-29 08:29:36

Additional Findings from RADAR Trial Published in Journal of Invasive Cardiology BASKING RIDGE, N.J., Jan. 29, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced the publication of additional findings from its completed Phase 2b RADAR trial in the Journal of Invasive Cardiology(1 )demonstrating the safety...

2013-08-19 10:14:30

Older heart patients present unique challenges for determining the optimal dosages of medications, so a new study from researchers at Duke Medicine offers some rare clarity about the use of drugs that are used to treat patients with heart attacks. For certain heart patients older than age 75, a half-dose of the anti-platelet drug prasugrel works about as well as the typical dosage of clopidogrel, according to a team led by the Duke Clinical Research Institute that looked at a sub-study of...

2011-08-15 08:35:00

INDIANAPOLIS and TOKYO, Aug. 15, 2011 /PRNewswire/ -- A new post-hoc sub-analysis of an important set of patients from the TRITON-TIMI 38 study - those identified as the "core clinical cohort" population - showed that treatment with prasugrel (in combination with aspirin) was associated with a 26 percent relative risk reduction in the combined primary endpoint of cardiovascular death, myocardial infarction or stroke, compared to treatment with clopidogrel (8.3 percent vs. 11.0 percent,...

2011-03-29 12:34:00

PARSIPPANY, N.J. and INDIANAPOLIS, March 29, 2011 /PRNewswire/ -- Oral antiplatelet therapy Effient® (prasugrel) has been added to the updated clinical practice guidelines as a Class I recommended treatment option for patients undergoing percutaneous coronary intervention (PCI) after experiencing heart-related chest pain at rest (unstable angina) or non-ST segment elevation myocardial infarction (NSTEMI). NSTEMI is a type of heart attack that that does not need to be...

2011-01-25 12:58:27

Two relatively simple methods, an ultrasound investigation and a blood test to measure the level of a substance known as BNP, can predict survival and future heart failure following acute coronary syndromes. This is the conclusion of a thesis presented at the University of Gothenburg, Sweden. Acute coronary syndromes, such as myocardial infarction and unstable angina, are among the most common causes of emergency medical care and death in Sweden for both women and men. "The ability to predict...

2010-08-31 20:33:20

Patients with acute coronary syndromes initially treated with the anticoagulant fondaparinux who underwent a coronary procedure (such as balloon angioplasty) and received a lower dose of the anticoagulant heparin during the procedure did not have a reduced rate of major bleeding and vascular access site complications, according to a study that will appear in the September 22 issue of JAMA. The study is being released early online to coincide with its presentation at the European Society of...

2010-08-16 15:49:28

The earlier that patients who suffer from atrial fibrillation obtain the correct treatment, the lower is the risk of serious secondary effects such as stroke. A thesis presented at the University of Gothenburg, Sweden, shows that a well-established measurement score can easily assess the risks for this patient group. The function of the heart is affected if it is subject to atrial fibrillation for a long period. It becomes successively more difficult to restore and maintain the normal heart...

2010-03-16 10:30:00

ATLANTA, March 16 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced results of a new analysis of the PLATO (A Study of PLATelet Inhibition and Patient Outcomes) study which showed there were fewer deaths in patients with acute coronary syndromes (ACS) who took the investigational oral antiplatelet ticagrelor (BRILINTA(TM)/BRILIQUE(TM)) within seven days prior to having heart bypass surgery (coronary artery bypass graft, CABG) compared to those who took clopidogrel.(1) These...


Word of the Day
cock-a-hoop
  • Exultant; jubilant; triumphant; on the high horse.
  • Tipsy; slightly intoxicated.
This word may come from the phrase 'to set cock on hoop,' or 'to drink festively.' Its origin otherwise is unclear. A theory, according to the Word Detective, is that it's a 'transliteration of the French phrase 'coq a huppe,' meaning a rooster displaying its crest ('huppe') in a pose of proud defiance.' Therefore, 'cock-a-hoop' would 'liken a drunken man to a boastful and aggressive rooster.'
Related